Background: Laryngeal angioedema may be associated with significant morbidity and even mortality. Because of the potential severity of attacks, both allergists and otolaryngologists must be knowledgeable about the recognition and treatment of laryngeal angioedema. This study describes the clinical characteristics and pathophysiology of bradykinin-mediated angioedema.
L aryngeal angioedema can be associated with significant morbidity or even mortality. [1] [2] [3] Treatment of laryngeal angioedema is therefore of critical importance to many physicians, most notably allergists, otolaryngologists, primary care physicians, and emergency medicine physicians. Effective treatment of laryngeal angioedema requires both an accurate diagnosis of the cause of the swelling as well as an appreciation of the underlying pathophysiology of the process. This review will summarize both the clinical characteristics and the pathophysiology of several of the most important causes of laryngeal angioedema.
Laryngeal angioedema, like all angioedema and urticaria, results from increased vascular permeability with movement of fluid from the vascular space to the interstitial space. [4] [5] [6] [7] This may occur from either a histamine-mediated process or a bradykinin-mediated process. The current review will focus on the pathophysiology of recurrent angioedema that is believed to be caused by bradykinin. The specific forms of recurrent angioedema covered will be hereditary angioedema (HAE), acquired C1 inhibitor (C1INH) deficiency, and angiotensin-converting enzyme (ACE) inhibitor-associated angioedema ( Fig. 1 ). Most of the discussion will focus on HAE because it is the most completely understood of these conditions. The accompanying article by Christiansen will then review the treatment of laryngeal angioedema. 8 
HAE WITH LOW C1INH ACTIVITY
HAE was first accurately described by Dr. William Osler in 1888. 1 Dr. Osler recognized the strong heritable nature of the disease and provided a very comprehensive description of the attacks in multiple generations of a single family. HAE is inherited in an autosomal dominant manner. It affects both male and female gender equally. Approximately 50% of the children of an affected parent will inherit the disease. In addition, the disease does not skip generations. Surveys of HAE patients and their families have revealed that only ϳ75% of patients with HAE have a positive family history of angioedema, with the other 25% of HAE patients having de novo mutations. 9 HAE is a rare disease, with an estimated prevalence of 1 per 50,000 in the general population. [10] [11] [12] There is no known ethnic difference in the prevalence of HAE. Because it is so uncommon, an accurate diagnosis of HAE must begin with the physician having a high index of suspicion based on the clinical characteristics (Table 1) . 11, 13, 14 Patients with HAE typically have recurrent angioedema without urticaria. The most commonly affected locations of swelling in HAE are the extremities, the gastrointestinal tract, the external genitourinary tract, the face, and the oropharynx/larynx. The probability that a given attack will involve the skin or abdomen is nearly 50% each. All other attack locations, including genitourinary and laryngeal attacks, account for only 3.6% of attacks. 15 Attacks of swelling in HAE patients are usually prolonged, with the swelling typically slowly increasing over ϳ24 hours and then resolving even more slowly over the subsequent 2-4 days. A clinical observation that is useful for suggesting that a patient might have HAE is the lack of a clear response to the standard medicines used to treat allergic swelling (antihistamines, corticosteroids, and epinephrine). 11, 13 Attacks are frequently but not always preceded by prodromal symptoms, most classically a serpiginous nonpruritic rash called erythema marginatum. 13, 16 The swelling in HAE is often quite severe and may be associated with considerable morbidity and even mortality. 11, 13, 14 The most
feared swelling in HAE is laryngeal attacks, which can occlude the airway and result in asphyxiation. [17] [18] [19] [20] [21] [22] Intubation may be lifesaving in an HAE patient with severe laryngeal angioedema; however, difficulty due to the distorted upper airway occasionally requires tracheotomy to preserve the airway. It is critically important to consider all patients with HAE at risk for asphyxiation because of laryngeal attacks, irrespective of whether they have ever had a laryngeal attack in the past or how severe their disease is. Over 50% of patients report having experienced at least one laryngeal attack. 15 Abdominal attacks frequently cause significant morbidity, including severe abdominal pain, nausea and vomiting, and orthostatic hypotension due to third spacing of fluid. The severe nature of these symptoms can mimic a surgical abdomen, and many HAE patients have undergone unnecessary abdominal surgery for HAE attacks. Patients frequently require treatment in the emergency department or even hospitalization for abdominal attacks. Narcotic addiction has been a problem in some HAE patients, because of the need for repeated treatments with potent opiate painkillers. Although often considered benign by physicians, even extremity attacks can prevent patients from going to work or attending school when they involve the dominant hand or the feet.
Approximately 50% of the patients began swelling before the age of 10 years, and almost all patients reported onset of symptoms before the age of 20 years. 13 Despite the importance of making the diagnosis, a delay of ϳ10-20 years between symptom onset and proper diagnosis has been observed. 13, 23 Attacks occur unpredictably, with varying frequency and severity. The average frequency of attacks in untreated HAE patients is unclear but variable. Disease severity is highly variable both between and sometimes within kindreds. Furthermore, no simple relationship has been observed between disease severity and plasma C1INH levels. Although most attacks occur without a clear precipitating factor, stress and minor trauma are each well recognized to be capable of provoking HAE attacks. Additionally, many women report that exogenous estrogens (from oral contraceptives or hormonal replace-ment therapy) significantly worsen attack frequency and severity. Pregnancy is associated with increased disease severity in about one-third of women; however, another third of women report lessened angioedema during pregnancy. A striking finding, however, is the lack of swelling that occurs at the time of parturition. 13 Once a diagnosis of HAE is suspected, confirming the diagnosis is usually straightforward and is based on laboratory measurement of the complement C4 level as well as the C1INH level or activity (Table 2) . 11, 24 
PATHOPHYSIOLOGY OF HAE WITH LOW C1INH ACTIVITY
In 1963, Dr. Virginia Donaldson found that patients with HAE were deficient in C1INH activity while their unaffected relatives as well as patients with other forms of angioedema and normal controls all had normal C1INH activity. 25 Two years later, Dr. Fred Rosen discovered that ϳ15% of HAE patients had normal C1INH levels but low C1INH activity (type II HAE) as opposed to the more common pattern of low C1INH levels and activity. 26 C1INH is a member of the serine protease inhibitor (serpin) superfamily. 27 Like other serpin inhibitors (such as ␣-1-antitrypsin and antithrombin), C1INH functions like a "molecular mousetrap." 28 Most of the structure is very rigid and under considerable stress; however, the reactive mobile loop, located at the top of the protein is mobile. The reactive mobile loop contains the active site where C1INH is attacked by its target proteases. Once a protease cleaves the peptide bond at the active site, there is a large-scale rearrangement of C1INH in which an arm of the reactive mobile loop inserts into the central ␤-sheet, trapping the target protease. There is a 1:1 stoichiometric relationship between the protease and C1INH, and each molecule of protease inhibited consumes one molecule of C1INH. The mechanism of inhibition thus involves a suicide inactivation. 29 The C1INH gene, SERPING1, is organized into eight exons with intervening introns. Disease causing mutations are scattered throughout the gene, in fact Ͼ200 different mutations associated with types I Figure 1 . Bradykinin-mediated angioedema. Hereditary angioedema (HAE), acquired C1 inhibitor (C1INH) deficiency, and angiotensin-converting enzyme (ACE) inhibitor-associated angioedema are all thought to result from bradykinin. Types I and II HAE as well as acquired C1INH deficiency are characterized by low C1INH functional activity, based on decreased synthesis or increased catabolism, respectively. The decreased C1INH activity prevents effective regulation of the contact system and results in enhanced bradykinin generation. Type III HAE may involve enhanced factor XII activity in at least some patients. The enhanced factor XII activity may lead to increased plasma kallikrein activation and enhanced bradykinin generation. ACE is an endopeptidase that degrades bradykinin, among other substrates. ACE inhibitors, therefore, may decrease the normal catabolism of bradykinin and lead to elevated bradykinin levels.
and II HAE have been described. Interestingly, mutations in the reactive mobile loop near or at the active site result in a dysfunctional protein that characterizes type II HAE. There is evidence that type I HAE often involves failure of the nascent protein to fold properly within the endoplasmic reticulum.
The mechanism by which a deficiency of C1INH causes increased vascular permeability and angioedema has been the subject of intense investigation over the past 30 years. Incubation of HAE plasma ex vivo at 37°C generates a factor that caused smooth muscle contraction and increased vascular permeability. 30 This "vascular permeability-enhancing factor" was correctly assumed to be the mediator of swelling in HAE; however, the final characterization of the factor remained elusive and controversial for many years.
C1INH is the principle inhibitor of several complement and contact system proteases as well as a minor inhibitor of coagulation factor XIa and plasmin. 27 During HAE attacks, each of these plasma proteolytic cascades is activated with the potential to generate several vasoactive compounds. Two potential mediators of swelling in HAE were identified as likely candidates to mediate enhanced vascular permeability in HAE: C2 kinin, generated through activation of the classic complement and fibrinolytic pathways, 31 and bradykinin, generated through activation of the contact system. 32 Despite initial suggestions that C2 kinin represented the vascular permeability-enhancing activity, compelling laboratory and clinical data have conclusively shown that bradykinin is the primary mediator of swelling in HAE. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] The nanopeptide bradykinin is generated when active plasma kallikrein cleaves high molecular weight kininogen. 43 Plasma kallikrein is activated from its inactive zymogen by the protease factor XII, and both plasma kallikrein and factor XII are normally inhibited by C1INH (Fig. 1) . The released bradykinin moiety potently increases vascular permeability by binding to its cognate receptor (the bradykinin B2-receptor) on vascular endothelial cells. Given the plethora of evidence supporting bradykinin as the mediator of swelling in HAE, it was of little surprise that drugs targeting bradykinin generation or action have shown efficacy during angioedema attacks. 44, 45 
TYPE III HAE
In 2000, two separate groups described a familial form of angioedema in which the C1INH was absolutely normal. 46, 47 Clinically, this new type of HAE (which is often called type III HAE) resembles types I and II HAE, although type III HAE presents at a somewhat older age and appears to have fewer abdominal and more facial attacks (Table 1) . 48 Type III HAE was initially thought to occur exclusively in women, particularly during times of increased estrogen exposure. Subsequently, affected men have been found 49, 50 ; and the strength of the relationship between estrogen exposure and angioedema is shown to be modest. 48 At the current time, there are no firm criteria for making a diagnosis of type III HAE; however, it should be considered in patients with recurrent angioedema who have a strong family history of angioedema as well as normal C1INH antigenic and functional levels and a normal C4 level ( Table 2) .
A mutation in the factor XII gene (Thr328Lys or Thr328Arg) that cosegregated with disease presence was described in some families with type III. 51 This mutation was reported to cause a gain-of-function in factor XII activity, an observation that was particularly exciting because a gain-of-function in factor XII would be expected to result in enhanced generation of bradykinin and thus explain the pathogenesis of this disorder (Fig. 1 ). Since then it has become clear that only a minority of families with type III HAE have a mutation in factor XII. 48 Furthermore, a recent study failed to confirm the gain-of-function in the mutant factor XII. 52 The genetic heterogeneity of type III HAE suggests that this diagnosis may encompass a heterogeneous group of disorders. Because type III HAE can clearly cause severe laryngeal angioedema, the lack of clear diagnostic or pathophysiological understanding of this disease is of significant concern and requires additional research.
ACQUIRED C1INH DEFICIENCY
In addition to its deficiency on a hereditary basis, C1INH deficiency also occurs in a sporadic acquired form (acquired C1INH deficiency). 53 These patients, who typically present in middle age or older, experience recurrent angioedema that is similar if not identical to HAE attacks. 54 Patients with acquired C1INH deficiency are also at significant risk for laryngeal attacks. Hereditary and acquired C1INH deficiencies are, however, relatively simple to differentiate based on the lack of family history and much later age of onset in the acquired form (Table 1) . Laboratory evaluation of acquired C1INH deficiency typically shows low C4 levels as well as low C1INH levels and activity similar to type I HAE; however, the C1q level is also frequently reduced in acquired C1INH deficiency but not in HAE (Table 2) . 55 The primary basis for the C1INH deficiency in acquired C1INH deficiency is increased catabolism of C1INH rather than decreased secretion of functional C1INH as found in HAE (Fig. 1) . 56, 57 The increased C1INH catabolism in acquired C1INH deficiency often related to underlying conditions. Many of these patients have tumors, particularly lymphoreticular malignancies, or other diseases that may consume C1INH. 58, 59 Importantly, successful treatment of the underlying disease may resolve the acquired C1INH deficiency. 60 Patients with acquired C1INH deficiency also frequently have autoantibodies directed to C1INH, not infrequently associated with a monoclonal gammopathy of unknown significance. 61, 62 The autoantibody has been shown to interfere with normal C1INH-protease interactions, favoring the degradation of C1INH into a smaller cleaved dysfunctional protein. 39, 63 ACE INHIBITOR-ASSOCIATED ANGIOEDEMA ACE inhibitors are a class of commonly used antihypertensive medications that are well recognized to be associated with angioedema in rare patients. 64 The angioedema associated with ACE inhibitor tends to show a predilection for involving the face, lips, tongue, and throat (Table 1) . 65 The overall prevalence of ACE inhibitor-induced angioedema is estimated to range from 1 per 1000 patients using these drugs. 66 A recent large study among patients in the United States Veterans Affairs system revealed an overall incidence of 1.97 cases per 1000 patients initiating ACE inhibitor therapy (compared with 0.51 cases per 1000 in patients initiating therapy with an antihypertensive drug other than an ACE inhibitor. 67 Substantial variation in the risk of developing angioedema are seen among subsets of patients with black patients having a nearly fourfold increase in risk and women having a 1.5-fold increase in risk. The risk of developing angioedema while using an ACE inhibitor is highest during the 1st month of treatment but does not disappear even in patients who have been taking an ACE inhibitor for years. 67, 68 The angioedema resulting from use of an ACE inhibitor occurs on a class-specific rather than a drug-specific basis. All patients who develop angioedema without urticaria while taking an ACE inhibitor should be suspected of potentially having ACE inhibitor-associated angioedema. Because this angioedema tends to be recurrent and potentially life-threatening when involving the larynx, 69, 70 patients who develop ACE inhibitor-associated angioedema must discontinue the use of all ACE-I drugs. Although there has been concern about switching patients who experience angioedema on an ACE inhibitor to an angiotensin receptor blocker, several studies have shown that there is no evidence of increased risk when such a patient is switched to an angiotensin receptor blocker. [71] [72] [73] The pathophysiology of ACE inhibitor-associated angioedema is thought to relate to decreased catabolism of bradykinin. ACE, also known as kininase 2, is an endopeptidase that degrades a variety of peptides including bradykinin (Fig. 1) . A drug (omapatrilat) that inhibited both ACE and neutral endopeptidase (which is also involved in the degradation of bradykinin) had a substantially increased risk of angioedema. 74 Furthermore, patients with a history of ACE inhibitor-associated angioedema were more likely than patients who tolerated ACE inhibitors without angioedema to have decreased plasma aminopeptidase P (another endopeptidase involved in the degradation of bradykinin) activity. 75 Other studies suggest that in addition to bradykinin, substance P (a peptide also degraded by ACE) may be involved in ACE inhibitor-associated angioedema. 76 
CONCLUSIONS
Bradykinin is a pluripotent peptide mediator, exerting different effects depending on the tissue in which it is generated. When generated in the vascular space, bradykinin can mediate enhanced vascular permeability-leading to movement of fluid from the vasculature space into the interstitial fluid (angioedema). Mechanistic studies have suggested (and in some cases proven) that increased levels of bradykinin are responsible for the angioedema associated with HAE, acquired C1INH deficiency, and ACE inhibitor-associated angioedema. Recognition of this fact is critically important because bradykinin-mediated angioedema is different in many key respects than the more common histamine-mediated angioedema. Severe laryngeal swelling is not infrequently encountered in bradykinin-mediated angioedema, and bradykinin-mediated angioedema does not respond to the drugs typically used to treat histamine-mediated angioedema. Furthermore, novel therapies are becoming available that for the first time provide effective treatment for bradykinin-mediated angioedema. Because the characteristics and treatment of these angioedemas are quite distinct from each other and histamine-mediated angioedema, it is crucial that the physician be able to recognize and distinguish these swelling disorders. 
